Amgen reveals favorable Phase 3 results for Uplizna® (inebilizumab-cdon) in treating generalized myasthenia gravis at AANEM 2024.

Golodirsen is a phosphorodiamidate morpholino oligomer (PMO), a class of synthetic oligonucleotides designed for high stability and resistance to enzymatic degradation. 

In a Phase 2/3 study, nipocalimab effectively controls symptoms in teenagers with generalized myasthenia gravis.

Beacon Therapeutics Reports Favorable 24-Month Results from Phase 2 SKYLINE Study of AGTC-501 in X-Linked Retinitis Pigmentosa Patients.

Topas Therapeutics released encouraging top-line outcomes from a Phase 2a study examining their leading candidate, TPM502.

Circle Pharma Begins Phase 1 Clinical Trial with CID-078, an Oral Cyclin A/B RxL Inhibitor, Administered to Initial Patients for Advanced Solid Tumors.

Transgene updates on Phase II trial for TG4001 cancer vaccine targeting recurrent or metastatic HPV16-positive cervical and anogenital cancers.

GSK shares favorable phase III findings from ANCHOR trials on depemokimab for chronic rhinosinusitis with nasal polyps.

A recent review in the journal Nature Reviews Clinical Oncology has explored new therapeutic approaches for multiple myeloma (MM) targeting cell membrane proteins.

SystImmune, Inc. has received FDA approval for its IND application regarding BL-M11D1 for patients with relapsed or refractory acute myeloid leukemia.

Repare Therapeutics has initiated dosing for the first patient in a Phase 1 clinical trial of RP-3467, an inhibitor of Polθ ATPase.

Dong-A ST declared that its biosimilar Imuldosa™ (ustekinumab-srlf/DMB-3115), which references Stelara®, has received approval from the U.S. Food and Drug Administration (FDA).